You are here

ZoneOne Pharma

Company Information
Address
1700 4th St, Suite 214, QB3 Garage, UCSF Mission bay Campus, MC2522
San Francisco, CA 94158
United States


http://www.zoneonepharma.com

Information

UEI: Q19PXJ661KK3

# of Employees: 4


Ownership Information

HUBZone Owned: Yes

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Non-irritating Sustained Release Cysteamine Eye Drops to Treat Cystinosis

    Amount: $238,466.00

    ABSTRACT The project goal is to develop a non irritating treatment for cystinosis induced corneal cystine crystal accumulation that can be administered approximately every hours Cystinosis is a rar ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  2. Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload

    Amount: $1,491,193.00

    DESCRIPTION provided by applicant We have devised a novel stable nanoliposome encapsulated desferoxamine DFO formulation LDFO for the treatment of iron overload Data from a pre clinical model ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  3. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    Amount: $298,920.00

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that ov ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
  4. Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload

    Amount: $160,664.00

    DESCRIPTION (provided by applicant): About 100,000 babies are born each year with severe thalassemia type blood disorders or sickle cell anemia, leading to a lifelong regime of blood transfusions. How ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  5. OTHER FUNCTIONS- RandD BIOMEDICAL (BASIC RESEARCH)

    Amount: $215,999.00

    The Hsp90 inhibitor 17-DMAG will be encapsulated in a nano-sized liposome formulation that is long-circulating with controlled drug release properties in tumor tissue. Reformulation of 17-DMAG in a na ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government